Reversing Autoimmunity Combination of Rituximab and Intravenous Immunoglobulin
In this concept paper, the authors present a unique and novel protocol to treat autoimmune diseases that may have the potential to reverse autoimmunity. It uses a combination of B cell depletion therapy (BDT), specifically rituximab (RTX) and intravenous immunoglobulin (IVIg), based on a specificall...
Main Authors: | A. Razzaque Ahmed, Srinivas Kaveri |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-07-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2018.01189/full |
Similar Items
-
B Cell Modulation Strategies in Autoimmune Diseases: New Concepts
by: Philippe Musette, et al.
Published: (2018-04-01) -
Intravenous immunoglobulin and immunomodulation of B cell - in vitro and in vivo effects
by: Milica eMitrevski, et al.
Published: (2015-01-01) -
Ross syndrome with ANA positivity: A clue to possible autoimmune origin and treatment with intravenous immunoglobulin
by: Vasudevan Biju, et al.
Published: (2010-01-01) -
Intravenous Immunoglobulin for Management of Non-paraneoplastic Autoimmune Retinopathy
by: Sahba Fekri, et al.
Published: (2020-04-01) -
Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections
by: Carlo Perricone, et al.
Published: (2021-01-01)